Economic burden of cardiomyopathy in Canada 2018 to 2021: opportunity for cost avoidance through pharmaceutical innovation. Brett J Skinner, PhD ABSTRACT This study estimated the economic illness associated with (CM), by hospital cost, productivity loss,